SCHEMBL13342802

SCHEMBL13342802

Cc1cc(Cl)ccc1OC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
MAPT P10636 2/20 0.47
GAA P10253 2/20 0.47
KDM4E B2RXH2 2/20 0.47
PKM P14618 1/20 0.47
HPGD P15428 1/20 0.47
ALOX12 P18054 1/20 0.47
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
P2RX3 P56373 2/20 0.41
CACNA1B Q00975 1/20 0.41
CTSL P07711 1/20 0.40
EPHX2 P34913 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
AAK1 Q2M2I8 1/20 0.39
P2RY2 P41231 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13342801 0.89 CACNA1B (0.48) ALDH1A1MAPTGAAKDM4EPKM
SCHEMBL13342790 0.85 AAK1 (0.50) ALDH1A1MAPTGAAKDM4EPKM
SCHEMBL13342805 0.85 TDP1 (0.49) ALDH1A1MAPTGAAKDM4EPKM
SCHEMBL13342795 0.82 EPHX2 (0.55) ALDH1A1MAPTGAAKDM4EPKM
SCHEMBL13342814 0.81 AAK1 (0.43) ALDH1A1MAPTGAAKDM4EPKM
SCHEMBL5607835 0.80 KDM4E (0.47) ALDH1A1MAPTGAAKDM4EPKM
SCHEMBL13342766 0.79 CYP1A2 (0.49) ALDH1A1MAPTGAAKDM4EHPGD
SCHEMBL13342778 0.79 TRPA1 (0.52) ALDH1A1MAPTGAAKDM4EPKM
SCHEMBL13342774 0.78 HPGD (0.51) ALDH1A1MAPTGAAKDM4EHPGD
SCHEMBL13342821 0.76 NPSR1 (0.46) MAPTKDM4ECTSLMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-05-06 US disclosed
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-05-06 US disclosed
US-7626042-B2 O-substituted hydroxyaryl derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-01 US disclosed
US-7626042-B2 O-substituted hydroxyaryl derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES RELA, NFKBIA, NFE2 ALDH1A1 366/4885MAPT 4188/4885GAA 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.